19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Health Sciences
Resources
Basic InformationLatest News
Diabetes Ups Risk of MACE in Acute Coronary SyndromesScientists Spot Genes Behind Skin ColorScientists Support Genome Editing to Prevent DiseaseBrain Disconnects Spotted in Parkinson's Patients With Visual HallucinationsCoffee Doesn't Help Parkinson's Motor DisordersCan Babies Help Heart Patients?Scientists Spot Marker for CTE in Living Football PlayersNerve Stimulation Pulls Patient From 15-Year Vegetative StateWhy Your Nose May Be Key to Parkinson's RiskEvolution Not Over for HumansBrain Scans Offer Clues to Why Some Teens Pile on PoundsNew Clues to Why Yawns Are ContagiousNew Hope From Old Drugs in Fight Against Parkinson'sFirst Gene Therapy Approved in U.S.Awake for Aneurysm Brain Surgery, Better Results?Does Autism Risk Reside in Cells' Energy Engines?More Evidence Contact Sports Can Affect the BrainVirtual House Calls for Speedy, Effective Parkinson's CareSeven Imaging Biomarkers Tied to Cognition in Male FightersDiabetes Drug Shows Promise Against Parkinson'sCombined MRI Might Help Predict Brain Damage in BoxersMedical Reality Catches Up to Science FictionNoninvasive Brain Test May Pinpoint Type of DementiaIn Mice, Brain Cells Discovered That Might Control AgingScans May Show Consciousness in 'Comatose' PatientsBoxers, MMA Fighters May Face Long-Term Harm to Brain: StudyFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Early Parkinson's May Prompt Vision ProblemsWhole-Genome Sequencing of Uncertain Clinical UtilityCould Shift Work Damage Your DNA?Gene Sequencing May Reveal Risks for Rare DiseasesRogue Genes May Cause Some ALS CasesSticky Brain 'Plaques' Implicated in Alzheimer's AgainEven Your Bones Can Get Fat, Mouse Study SuggestsDoes a Low-Fat Dairy Habit Boost Parkinson's Risk?MicroRNA Biomarker Signature Identified for Allergic AsthmaHaywire Immune Cells May Help Cause BaldnessRegion in Brain Associated With Fear of Uncertain FutureBrain Scans Spot Where Fear and Anxiety LiveGene Therapy Might Someday Mend Badly Broken BonesLife Expectancy Slighter Shorter With Parkinson's, DementiaStudy Looks at Parkinson's Effect on Life SpanBody Cooling May Help Brain After Cardiac ArrestDo You Overeat? Your Brain Wiring May Be WhyGene Mutation May Speed Alzheimer's DeclineIs This Enzyme Making You Fat?Type 2 Diabetes May Be Bad for Brain Health'Brain Age' May Help Predict When You'll DieParkinson's Disease May Originate in Gut, Study SaysBlood-Based Genome Testing Feasible for Rapid Mutation Assay
Questions and AnswersVideosLinksBook Reviews
Related Topics

Mental Disorders
Mental Health Professions
Alzheimers Disease and other Cognitive Disorders

FDA Approves 1st Direct-to-Consumer Genetic Risk Tests

HealthDay News
by -- Scott Roberts
Updated: Apr 6th 2017

THURSDAY, April 6, 2017 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved the first direct-to-consumer genetic health risk tests.

Known as the 23andMe Personal Genome Service Genetic Health Risk tests, they assess a person's inherited risk for 10 diseases and conditions.

"Consumers can now have direct access to certain genetic risk information," said Dr. Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health. "But it is important that people understand that genetic risk is just one piece of the bigger puzzle, it does not mean they will or won't ultimately develop a disease."

The tests may be used to "make decisions about lifestyle choices or to inform discussions with a health care professional," the agency said in a news release.

The tests derive DNA from a saliva sample, which is then screened for more than 500,000 genetic variants that are associated with an increased risk for the following diseases or conditions:

  • Parkinson's disease;
  • Alzheimer's disease (late onset);
  • Celiac disease;
  • Antitrypsin deficiency (Alpha-1), a disorder that raises the risk of lung and liver disease;
  • Primary dystonia (early onset), a movement disorder involving involuntary muscle contractions and other uncontrolled movements;
  • Factor XI deficiency, a blood clotting disorder;
  • Gaucher disease (type 1), an organ and tissue disorder;
  • Glucose-6-Phosphate Dehydrogenase deficiency; a red blood cell condition;
  • Hemochromatosis (hereditary), an iron overload disorder;
  • Thrombophilia (hereditary); a blood clot disorder.

The agency said it had established "special controls" to clarify its expectations of how well the tests should perform. The FDA said it also had crafted streamlined procedures to make it easier for other makers to develop and submit similar tests for approval.

The agency said in approving the tests, made by 23andMe Inc. in Mountain View, Calif., it analyzed data from peer-reviewed studies that demonstrated "a link between specific genetic variants and each of the 10 health conditions."

The FDA did warn that the tests could yield false-positive results, indicating incorrectly that a person has a certain genetic variant that would increase risk of a particular disease or condition. Test results should not be used to diagnose or treat a specific illness, the agency added.

More information

To learn more about this approval, visit the FDA.